JP2025515917A5 - - Google Patents
Info
- Publication number
- JP2025515917A5 JP2025515917A5 JP2024568240A JP2024568240A JP2025515917A5 JP 2025515917 A5 JP2025515917 A5 JP 2025515917A5 JP 2024568240 A JP2024568240 A JP 2024568240A JP 2024568240 A JP2024568240 A JP 2024568240A JP 2025515917 A5 JP2025515917 A5 JP 2025515917A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- androgen receptor
- ligand
- breast cancer
- negative breast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210536761.3 | 2022-05-17 | ||
| CN202210536761 | 2022-05-17 | ||
| PCT/CN2023/094686 WO2023222011A1 (zh) | 2022-05-17 | 2023-05-17 | 一种治疗三阴乳腺癌的联合用药物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025515917A JP2025515917A (ja) | 2025-05-20 |
| JP2025515917A5 true JP2025515917A5 (enExample) | 2026-05-19 |
Family
ID=88708606
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024566686A Pending JP2025514558A (ja) | 2022-05-17 | 2023-05-17 | トリプルネガティブ乳癌を治療するための薬物 |
| JP2024568240A Pending JP2025515917A (ja) | 2022-05-17 | 2023-05-17 | トリプルネガティブ乳癌を治療するための併用薬物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024566686A Pending JP2025514558A (ja) | 2022-05-17 | 2023-05-17 | トリプルネガティブ乳癌を治療するための薬物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20250082764A1 (enExample) |
| EP (2) | EP4527383A4 (enExample) |
| JP (2) | JP2025514558A (enExample) |
| KR (2) | KR20250011955A (enExample) |
| CN (2) | CN117065022A (enExample) |
| AU (1) | AU2023273852A1 (enExample) |
| CA (2) | CA3253882A1 (enExample) |
| WO (2) | WO2023222012A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021020775A2 (pt) * | 2019-04-18 | 2021-12-14 | Hinova Pharmaceuticals Inc | Classe de compostos heterocíclicos quiméricos bifuncionais para a degradação direcionada de receptores de andrógeno e uso dos mesmos |
| CN115996918A (zh) | 2020-05-09 | 2023-04-21 | 阿尔维纳斯运营股份有限公司 | 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型 |
| WO2025085738A1 (en) | 2023-10-18 | 2025-04-24 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
| AU2024392985A1 (en) | 2023-12-08 | 2026-06-04 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
| WO2025152998A1 (en) * | 2024-01-17 | 2025-07-24 | Foshan Ionova Biotherapeutics Co., Inc. | Compounds for the targeted degradation of androgen receptor and use thereof |
| WO2025189056A1 (en) | 2024-03-08 | 2025-09-12 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| WO2026061104A1 (zh) * | 2024-07-05 | 2026-03-26 | 甘李药业股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10806720B2 (en) * | 2015-04-21 | 2020-10-20 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| KR20210120819A (ko) * | 2018-05-16 | 2021-10-07 | 온크터널 테라퓨틱스 인코포레이티드 | 선택적 안드로겐 수용체 분해제(sard) 리간드 및 이의 사용 방법 |
| WO2020198710A1 (en) * | 2019-03-28 | 2020-10-01 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| BR112021020775A2 (pt) * | 2019-04-18 | 2021-12-14 | Hinova Pharmaceuticals Inc | Classe de compostos heterocíclicos quiméricos bifuncionais para a degradação direcionada de receptores de andrógeno e uso dos mesmos |
| EP4029499A4 (en) * | 2019-06-12 | 2023-07-26 | Shanghaitech University | Alk protein regulator and anti-tumor application thereof |
| WO2021087093A1 (en) * | 2019-10-30 | 2021-05-06 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of helios and methods of use |
| IL295841A (en) * | 2020-02-25 | 2022-10-01 | Univ Tennessee Res Found | and methods for their use (sard) selective androgen receptor cleaving ligands |
| EP4168007A1 (en) * | 2020-06-23 | 2023-04-26 | Novartis AG | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| IL301690A (en) * | 2020-10-16 | 2023-05-01 | Dana Farber Cancer Inst Inc | Piperidinyl small molecule degraders of helios and methods of use |
| JP2024539269A (ja) * | 2021-10-22 | 2024-10-28 | グルータクス セラピューティクス （シャンハイ） カンパニー、リミテッド | Ｃｒｂｎ ｅ３リガーゼリガンド化合物、当該リガンド化合物に基づいて開発したタンパク質分解剤及びそれらの応用 |
| WO2023069700A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
| TW202341988A (zh) * | 2022-03-25 | 2023-11-01 | 密西根大學董事會 | Ｉｋｚｆ２降解劑及其用途 |
| WO2024006527A1 (en) * | 2022-07-01 | 2024-01-04 | Arvinas Operations, Inc. | Breast cancer treatment method |
| WO2024010818A2 (en) * | 2022-07-07 | 2024-01-11 | University Of Tennessee Research Foundation | Proteolysis targeting chimera (protac) of selective androgen receptor degrader (sard) compounds and methods of use thereof |
-
2023
- 2023-05-16 CN CN202310550985.4A patent/CN117065022A/zh active Pending
- 2023-05-16 CN CN202310550983.5A patent/CN117065033A/zh active Pending
- 2023-05-17 JP JP2024566686A patent/JP2025514558A/ja active Pending
- 2023-05-17 KR KR1020247041760A patent/KR20250011955A/ko active Pending
- 2023-05-17 EP EP23806963.7A patent/EP4527383A4/en active Pending
- 2023-05-17 WO PCT/CN2023/094688 patent/WO2023222012A1/zh not_active Ceased
- 2023-05-17 KR KR1020247041759A patent/KR20250011189A/ko active Pending
- 2023-05-17 WO PCT/CN2023/094686 patent/WO2023222011A1/zh not_active Ceased
- 2023-05-17 AU AU2023273852A patent/AU2023273852A1/en active Pending
- 2023-05-17 JP JP2024568240A patent/JP2025515917A/ja active Pending
- 2023-05-17 CA CA3253882A patent/CA3253882A1/en active Pending
- 2023-05-17 CA CA3253774A patent/CA3253774A1/en active Pending
- 2023-05-17 EP EP23806962.9A patent/EP4527388A4/en active Pending
-
2024
- 2024-11-18 US US18/950,929 patent/US20250082764A1/en active Pending
- 2024-11-18 US US18/950,818 patent/US20250082763A1/en active Pending